Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective

Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective

Bhavani Shankara Bagepally,1,2 Usa Chaikledkaew,1,3 Sitaporn Youngkong,1,3 Thunyarat Anothaisintawee,1,4 Montarat Thavorncharoensap,1,3 Charungthai Dejthevaporn,5 Ammarin Thakkinstian1,6 1Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand;...

Full description

Bibliographic Details
Main Authors: Bagepally BS, Chaikledkaew U, Youngkong S, Anothaisintawee T, Thavorncharoensap M, Dejthevaporn C, Thakkinstian A
Format: Article
Language:English
Published: Dove Medical Press 2021-10-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
economic evolution
cost-effectiveness
sodium glucose transporter 2 inhibitor
type 2 diabetes
india
glibenclamide
gliclazide
Online Access:https://www.dovepress.com/cost-utility-analysis-of-dapagliflozin-compared-to-sulfonylureas-for-t-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/cost-utility-analysis-of-dapagliflozin-compared-to-sulfonylureas-for-t-peer-reviewed-fulltext-article-CEOR

Similar Items